Gemcitabine-resistant pancreatic cancer: a second-line option
Authors:
Open Access
- 23 November 2015
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 387 (10018) , 507-508
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Preclinical Activity of Nanoliposomal Irinotecan Is Governed by Tumor Deposition and Intratumor Prodrug ConversionCancer Research, 2014
- Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981–2010Scientific Reports, 2014
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 TrialJournal of Clinical Oncology, 2014
- Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedsideCancer Treatment Reviews, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic CancerNew England Journal of Medicine, 2011
- A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBritish Journal of Cancer, 2006
- Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response RateJournal of Clinical Oncology, 2004